Similar articles for PMID: 33376103

1

Cite

Share

Long-Term Safety of Tolvaptan in ADPKD: Where Do We Stand?

Patel DM, Dahl NK. Patel DM, et al. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):3-5. doi: 10.2215/CJN.17981120. Epub 2020 Dec 29. Clin J Am Soc Nephrol. 2020. PMID: 33376103 No abstract available.

Cite

Share

2

Cite

Share

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.

Bennett H, McEwan P, Hamilton K, O'Reilly K. Bennett H, et al. BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5. BMC Nephrol. 2019. PMID: 31014270 Free PMC article. Clinical Trial.

Cite

Share

3

Cite

Share

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Torres VE, et al. Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17. Am J Kidney Dis. 2011. PMID: 21333426 Clinical Trial.

Cite

Share

4

Cite

Share

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23. Clin J Am Soc Nephrol. 2016. PMID: 26912543 Free PMC article. Clinical Trial.

Cite

Share

5

Cite

Share

Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience.

Guerra-Torres XE, Peña Esparragoza J, Perez Fernandez M, Fernandez Rodríguez M, Mancha Ramos J, Martinez Miguel P, Rodriguez Puyol D, Bouarich H. Guerra-Torres XE, et al. Cureus. 2020 Sep 2;12(9):e10207. doi: 10.7759/cureus.10207. Cureus. 2020. PMID: 33033683 Free PMC article.

Cite

Share

6

Cite

Share

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.

Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, Shi L, Dandurand A, Sikes K, Shoaf SE. Schaefer F, et al. Eur J Pediatr. 2019 Jul;178(7):1013-1021. doi: 10.1007/s00431-019-03384-x. Epub 2019 May 3. Eur J Pediatr. 2019. PMID: 31053954 Free PMC article.

Cite

Share

7

Cite

Share

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT. Boertien WE, et al. Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15. Am J Kidney Dis. 2015. PMID: 25600953

Cite

Share

8

Cite

Share

Effect of tolvaptan in a patient with autosomal dominant polycystic kidney disease after living donor liver transplantation.

Uchiyama K, Honda K, Yoshida R, Kamijo Y, Yanagi M, Nakatsuka M, Ishibashi Y. Uchiyama K, et al. CEN Case Rep. 2016 Nov;5(2):227-231. doi: 10.1007/s13730-016-0230-5. Epub 2016 Jul 27. CEN Case Rep. 2016. PMID: 28508983 Free PMC article.

Cite

Share

9

Cite

Share

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE. Edwards ME, et al. Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19. Clin J Am Soc Nephrol. 2018. PMID: 30026287 Free PMC article. Clinical Trial.

Cite

Share

10

Cite

Share

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS. Devuyst O, et al. J Am Soc Nephrol. 2017 May;28(5):1592-1602. doi: 10.1681/ASN.2016040448. Epub 2016 Dec 5. J Am Soc Nephrol. 2017. PMID: 27920153 Free PMC article. Clinical Trial.

Cite

Share